Results 51 to 60 of about 23,640 (262)

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those
Alisha Sharma, Alyssa Y. Li, Teruko Kishibe, Dennis Wong, Kevin M. Sanders, Maggie Jiang, Heedo Lee, Christine Song, Kieran Mcintyre, Christian Pagnoux, Yvonne Chan, John M. Lee, Daniel J. Lee   +12 more
wiley   +1 more source

Assessing Surgical Extent Before Biologic Therapy for CRSwNP

International Forum of Allergy &Rhinology, EarlyView.
Key points Nearly two‐thirds of patients had no surgery or incomplete sinus surgery before biologics. Among all sinuses, the frontal sinus was the least frequently addressed before biologics.
Alison J. Yu, Kristina A. LaPointe, Kaitlyn Ann Roberts, Michelle Yu, James N. Palmer, Alan D. Workman, Jose L. Mattos, Rodney J. Schlosser, Zachary M. Soler   +8 more
wiley   +1 more source

Correlation of Local Nasal Biomarkers and Olfactory Dysfunction in Chronic Rhinosinusitis: A Systematic Review and Meta‐Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background To systematically evaluate the local biomarkers correlated with olfactory dysfunction (OD) in chronic rhinosinusitis (CRS). Methods A systematic review was conducted in CINAHL, Cochrane Library, PubMed, and Scopus from inception to July 2025.
David Kayekjian, Neeti Gandra, Shaun A. Nguyen, Shaina W. Twardus, Rodney J. Schlosser   +4 more
wiley   +1 more source

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons

Cells
Asthma is a prevalent chronic non-communicable disease, affecting approximately 300 million people worldwide. It is characterized by significant airway inflammation, hyperresponsiveness, obstruction, and remodeling.
Musaddique Hussain, Gang Liu
doaj   +1 more source

Clinical Longitudinal Evaluation After Regimen Stop (CLEAR) of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Long‐term management strategies for severe chronic rhinosinusitis with nasal polyps (CRSwNP) increasingly include biologic therapy targeting Type 2 inflammation. However, data on outcomes after complete discontinuation of dupilumab following sustained disease control are scarce.
Patrick Huber, Manuel Lasch, Veronika Volgger, Clemens Stihl, Philipp Teupe, Fabienne Oettgen, Sophia Gantner, Moritz Gröger   +7 more
wiley   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma

Mediators of Inflammation, 2015
Asthma is a phenotypically heterogeneous chronic disease of the airways, characterized by either predominant eosinophilic or neutrophilic, or even mixed eosinophilic/neutrophilic inflammatory patterns. Eosinophilic inflammation can be associated with the
Girolamo Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Luca Gallelli, Cecilia Calabrese, Rosa Terracciano, Rosario Maselli   +6 more
doaj   +1 more source

Mepolizumab, quality of life, and severe eosinophilic asthma [PDF]

The Lancet Respiratory Medicine, 2017
It is now ten years since the publication of the first clinical trial, eight years since the first key proof of concept studies in a population selected on the basis of inflammatory pattern and two years since approval of Mepolizumab as a treatment for severe eosinophilic asthma.
openaire   +3 more sources

Tracheal wash culture is not associated with bronchial infection, remodelling or inflammation in horses with asthma

Equine Veterinary Journal, EarlyView.
Abstract Background Antimicrobials are commonly prescribed for the treatment of equine asthma, despite limited evidence supporting their use. Tracheal wash (TW) bacterial culture results are known to influence antimicrobial prescription decisions. Objectives To determine whether a positive TW bacterial culture in horses with asthma is associated with ...
Laurence Leduc, Guillaume St‐Jean, Jean‐Pierre Lavoie   +2 more
wiley   +1 more source

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis

JPGN Reports, EarlyView.
Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley   +1 more source